56 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Article Searches
Institutional Top Ideas Series: Opaleye Management https://seekingalpha.com/article/4174919-institutional-top-ideas-series-opaleye-management?source=feed_all_articles May 17, 2018 - Opaleye Management is a smaller fund with exceptional performance of late.Their top two holdings are heavily weighted and they are capitalizing on the targeted oncology theme as well.I provide a brief
JF's Core Biotech Buys #15: Removal Of A Key Overhang, Buying Weakness In I-O, Updates And Adding To 2 Positions https://seekingalpha.com/article/4173708-jfs-core-biotech-buys-15-removal-key-overhang-buying-weakness-o-updates-adding-2-positions?source=feed_all_articles May 14, 2018 - Although this series is focused on the long term I continue to be pleased with our performance so far.President Trump´s speech on drug prices removed a key overhang for biotech (please see my blog pos
Pushing Preclinical: Wave Of Early-Stage Biotech IPOs Tests Investor Risk Appetite https://seekingalpha.com/article/4171623-pushing-preclinical-wave-early-stage-biotech-ipos-tests-investor-risk-appetite?source=feed_tag_ipo_analysis May 09, 2018 - Biotechs are among the most risky of IPOs due to the binary nature of the success… or failure of their drugs. In the past, most biotechs delayed public offerings until they at least showed clinical ev
JF's Core Biotech Buys #14: Introducing Our Final 2 Positions & Taking Advantage Of Weakness In The I-O Space https://seekingalpha.com/article/4170858-jfs-core-biotech-buys-14-introducing-final-2-positions-and-taking-advantage-weakness-o-space?source=feed_all_articles May 07, 2018 - The M&A theme appears set to continue in the spotlight this year, with Gilead to put cash to work and Takeda likely to come to terms with Shire.President Trump´s drug pricing speech is expected soon a
Institutional Top Ideas Series: Orbimed Advisors https://seekingalpha.com/article/4169731-institutional-top-ideas-series-orbimed-advisors?source=feed_all_articles May 04, 2018 - Today's fund in the spotlight, Orbimed Advisors, is quite large and in the midst of a leadership transition. They avoid outsized bets (over 5% weighting) yet still post decent returns.I provide a brie
Blueprint Medicines 2018 Q1 - Results - Earnings Call Slides https://seekingalpha.com/article/4168744-blueprint-medicines-2018-q1-results-earnings-call-slides?source=feed_sector_healthcare May 02, 2018 - The following slide deck was published by Blueprint Medicines in conjunction with their 2018 Q1 earnings call.
Blueprint Medicines' (BPMC) CEO Jeff Albers on Q1 2018 Results - Earnings Call Transcript https://seekingalpha.com/article/4168742-blueprint-medicines-bpmc-ceo-jeff-albers-q1-2018-results-earnings-call-transcript?source=feed_sector_healthcare May 02, 2018 - Blueprint Medicines Corp. (NASDAQ:BPMC) Q1 2018 Earnings Conference Call May 2, 2018 8:30 AM ET Executives Kristin Hodous – Investor Relations Jeff Albers – Chief Executive Officer Andy Boral – Chief
JF's Core Biotech Buys #13: Continued Market Headwinds And How To Respond https://seekingalpha.com/article/4167853-jfs-core-biotech-buys-13-continued-market-headwinds-respond?source=feed_all_articles May 01, 2018 - The thesis for position #18, Ionis Pharmaceuticals, has been added.Weakness in the overall market and biotech sector continues to frustrate (and scare) many investors.I remind readers that I am not a
JF's Core Biotech Buys #12: Updates And Introducing Our 18th Selection https://seekingalpha.com/article/4165041-jfs-core-biotech-buys-12-updates-introducing-18th-selection?source=feed Apr 24, 2018 - President Trump´s speech on drug pricing has been postponed. Continued deal activity in the biotech sector bodes well. Abeona Therapeutics announced receipt of the FDA´s RMAT (Regenerative Medicine Ad
JF's Core Biotech Buys #11: Positive News For Several Holdings, A Change To Benchmarks And Introducing Our 17th Position https://seekingalpha.com/article/4163485-jfs-core-biotech-buys-11-positive-news-several-holdings-change-benchmarks-introducing-17th?source=feed_all_articles Apr 17, 2018 - Performance of the Core Biotech Model Account is currently tracking just ahead of the IBB and XBI over the same period of time.I explain below why I´ve made the choice to use dual benchmarks instead o

Pages: 123456

Page 1>
DeepLinks for Blueprint Medicines
BPMC - Google Finance https://www.google.com/finance?q=BPMC Industry related info and international coverage Summary News
BPMC - Bloomberg http://www.bloomberg.com/research/stocks/snapshot/snapshot.asp?ticker=BPMC Original news and commentary from Bloomberg Charts Financials with pensions Snapshot Earnings Transactions People Options